Pharmaceutical

Esperion snags US label expansion for cardiovascular disease drugs

Esperion Therapeutics’ Nexletol and Nexlizet are now available for patients with cardiovascular risk in the US.

Mar 26, 2024 - 00:00
Esperion snags US label expansion for cardiovascular disease drugs
Esperion Therapeutics’ Nexletol and Nexlizet are now available for patients with cardiovascular risk in the US.
Read the original article

Tags:

Previous Article

CRISPR-based assay could revolutionise diagnosis of NTM infections

Next Article

AriBio licenses Alzheimer’s pill in China for up to $770m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Expansive investigation into Stanford president’s past research will be ‘substantially complete’ by mid-July

Expansive investigation into Stanford president’s past ...

May 1, 2023

SNIPR celebrates US court’s favourable ruling on CRISPR patent

SNIPR celebrates US court’s favourable ruling on CRISPR...

Jul 17, 2023

Cross-border ‘twinning programs’ may reduce survival disparities for childhood leukemia

Cross-border ‘twinning programs’ may reduce survival di...

Jun 4, 2023